Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Phase 2 Completed 35 enrolled Kite, A Gilead Company

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Timeline

Start: 2022-08-09
Primary completion: 2025-11-24
Completion: 2025-11-24

Publications

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark W, Rapoport AP, Rodriguez TE, Winters JN, Davis M, Miao HM, Ray M, Fang X, Kim JJ, Oluwole OO. Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. Am J Cancer Res. 2025 Aug 15;15(8):3417-3433. doi: 10.62347/GJNN1023. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axicabtagene Ciloleucel	Cell therapy	2e+06 cells/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	500 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	10 mg	Oral
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications